Would you use first line combination immunotherapy with chemotherapy in patients with metastatic low ER/PR+ (<10%), HER2 negative breast cancer?  

Given that trials excluded patients with low ER, PR for this approach. 

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Rutgers Cancer Institute of New Jersey
Have you been able to obtain Pd-1 scores on these ...
Medical Oncologist at University of North Carolina at Chapel Hill
Yes, we’ve had a few cases where we were abl...
Sign in or Register to read more